^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:patritumab deruxtecan (U3-1402) (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

    Excerpt:
    ...Participants with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (eg, ALK or ROS1 fusion) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy....
    Trial ID:
    U31402-A-U102
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

    Published date:
    05/26/2022
    Excerpt:
    At the Mar 26, 2021, data cutoff, 47 pts had been treated with HER3-DXd 5.6 mg/kg IV every 3 wk; 17 pts had an identified driver genomic alteration (4 KRAS and 1 NRAS mutations, 4 EGFR Ex20ins, 3 ROS1 and 2 ALK fusions, and 3 other).
    DOI:
    10.1200/JCO.2022.40.16_suppl.9017
    Trial ID:
    U31402-A-U102